Virtus LifeSci Biotech Products ETF
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0.68% more ownership
Funds ownership: 21.88% [Q3] → 22.56% (+0.68%) [Q4]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
2% less capital invested
Capital invested by funds: $4.81M [Q3] → $4.74M (-$72.4K) [Q4]
8% less funds holding
Funds holding: 13 [Q3] → 12 (-1) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for BBP.
Financial journalist opinion
Neutral
Seeking Alpha
2 weeks ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

Positive
Zacks Investment Research
8 months ago
4 Best-Performing Sector ETFs of June
We have highlighted four top-performing ETFs from different sectors that have led the way in June.

Positive
Zacks Investment Research
1 year ago
Biotech ETFs Stage Solid Comeback at the Start of 2024
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.
Charts implemented using Lightweight Charts™